T1	Participants 123 211	patients with common cancers involving bone receiving intravenous bisphosphonate therapy
T2	Participants 476 515	Enrolled in the study were 184 patients
T3	Participants 1023 1044	subset of 43 patients
T4	Participants 1758 1773	Cancer patients
